EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting Hippo/YAP in intrahepatic cholangiocarcinoma: Promising molecules in cancer therapy

Xing Ma iD, Yangyang Zhou, Ruping Li, Xianmin Ding, Deyu Li, Tingting Pan, Fuqiang Zhang, Wenliang Li

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23791 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Xing Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Protein Serine-Threonine Kinases, Hippo Signaling Pathway. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Henan Medical Science and Technology Breakthrough Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumorigenesis of intrahepatic cholangiocarcinoma (ICC) has been identified to be exceptionally involved in dysregulated Hippo/Yes‐associated protein (YAP) signaling pathway (Hippo/YAP). Hippo/YAP functions as a master regulator engaged in a plethora of physiological and oncogenic processes as well. Therefore, the aberrant Hippo/YAP could serve as an Achilles' heel regarding the molecular therapeutic avenues for ICC patients. Herein, we comprehensively review the recent studies about the underlying mechanism of disrupted Hippo/YAP in ICC, how diagnostic values could be utilized upon the critical genes in this pathway, and what opportunities could be given upon this target pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsProtein Serine-Threonine KinasesHippo Signaling PathwayTranscription FactorsSignal TransductionYAP-Signaling ProteinsHumansAdaptor Proteins, Signal TransducingAnimalsMolecular Targeted TherapyGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Hippo/YAPHippo/Yes‐associated proteindiagnosisintrahepatic cholangiocarcinomatherapy

Substanzen

Protein Serine-Threonine KinasesTranscription FactorsYAP-Signaling ProteinsYAP1 protein, humanAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Xing Ma

Förderung

  • Henan Medical Science and Technology Breakthrough Plan

Zitieren

APA

Ma, X., Zhou, Y., Li, R., Ding, X., Li, D., Pan, T., Zhang, F., & Li, W. (2024). Targeting Hippo/YAP in intrahepatic cholangiocarcinoma: Promising molecules in cancer therapy. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23791

Vancouver

Ma X, Zhou Y, Li R, Ding X, Li D, Pan T, et al. Targeting Hippo/YAP in intrahepatic cholangiocarcinoma: Promising molecules in cancer therapy. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23791

BibTeX
@article{Ma2024,
  author = {Ma, Xing and Zhou, Yangyang and Li, Ruping and Ding, Xianmin and Li, Deyu and Pan, Tingting and Zhang, Fuqiang and Li, Wenliang},
  title = {Targeting Hippo/YAP in intrahepatic cholangiocarcinoma: Promising molecules in cancer therapy},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23791}
}
Kostenlos starten →